Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma

Part of paid clinical trials in Gainesville, Florida.

Sponsor
University of Florida
Study ID
NCT07560709
Status
No Longer Available

Conditions

  • Recurrent Osteosarcoma

Eligibility Criteria

Sex
MALE
Age
15 Years - 17 Years
Healthy Volunteers
Not accepted

Interventions

  • pp65/tumor mRNA RNA-LP — BIOLOGICAL
    Autologous total tumor mRNA and pp65 full length (fl) lysosomal associated membrane protein (LAMP) mRNA loaded DOTAP liposome vaccine administered intravenously (RNA loaded lipid particles, RNA-LPs)

Study Details

Treatment of a patient with recurrent osteosarcoma with personalized pp65/tumor mRNA RNA-LP under an individual patient expanded access protocol.

Key Dates

Status verified
Apr 2026

Locations (1)

FacilityCityStateZIPSite coordinators
University of Florida HealthGainesvilleFlorida32608-

Find similar trials in Gainesville, FL

By research site
University of Florida Health· Gainesville, FL

Related Studies